Kurlander Jacob E, Robinson Claire H, Parra David, Evans Lacey, Moore Von, Barnes Geoffrey D, Ranusch Allison A, Sussman Jeremy B
VA Ann Arbor Healthcare System Center for Clinical Management Research, PO Box 130170, Ann Arbor, MI, 48113-0170, USA.
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Int J Clin Pharm. 2025 Jun 4. doi: 10.1007/s11096-025-01922-2.
The combined use of antiplatelet medications with direct oral anticoagulants increases patients' risk of hemorrhage. In 2021, a multistate network of Veterans Affairs medical centers in the United States deployed a successful multicomponent stewardship initiative to reduce inappropriate anticoagulant-antiplatelet therapy.
Identify barriers, facilitators, and potential adaptations of the initiative to guide broader dissemination.
Clinical pharmacists and pharmacist managers were invited to participate in semi-structured interviews about their experiences with the initiative. Interviews were transcribed. Thematic analysis was informed by the Consolidated Framework for Implementation Research (CFIR).
Fifteen interviews were completed (response rate 68%). The initiative was considered important and worth disseminating, and the addition of a visual alert to flag potential deprescribing candidates on an anticoagulation population management dashboard was considered especially beneficial. Three primary themes were identified using the CFIR. First, pharmacists often encountered barriers to coordination across specialties, with some clinicians unconvinced of the clinical evidence favoring antiplatelet deprescribing; breaking down these clinical silos, through targeted education and identifying meaningful clinician champions, is essential to increasing success of this initiative. Second, pharmacists sought clarification about how their deprescribing efforts, a relatively new activity, would be accounted for in performance evaluations, and how clinics would meet increased staffing needs. Third, adaptability of the initiative to local context was considered valuable.
As part of a multicomponent oral anticoagulant-antiplatelet stewardship initiative, preventing clinical silos, clarifying expectations around performance and staffing, and permitting adaptations to local context are important to maximizing impact.
抗血小板药物与直接口服抗凝剂联合使用会增加患者出血风险。2021年,美国退伍军人事务医疗中心的一个多州网络成功开展了一项多组分管理倡议,以减少不适当的抗凝 - 抗血小板治疗。
确定该倡议的障碍、促进因素和潜在调整措施,以指导更广泛的传播。
邀请临床药师和药师管理人员参与关于他们在该倡议方面经验的半结构化访谈。访谈内容进行了转录。采用实施研究综合框架(CFIR)进行主题分析。
完成了15次访谈(回复率68%)。该倡议被认为很重要且值得传播,并且在抗凝人群管理仪表板上添加视觉警报以标记潜在的减药候选人被认为特别有益。使用CFIR确定了三个主要主题。首先,药师在跨专业协调方面经常遇到障碍,一些临床医生不相信支持停用抗血小板药物的临床证据;通过有针对性的教育和确定有影响力的临床倡导者来打破这些临床壁垒,对于提高该倡议的成功率至关重要。其次,药师寻求澄清他们的减药工作(一项相对较新的活动)在绩效评估中将如何被考量,以及诊所将如何满足增加的人员配备需求。第三,该倡议对当地情况的适应性被认为很有价值。
作为多组分口服抗凝剂 - 抗血小板管理倡议 的一部分,防止临床壁垒、明确围绕绩效和人员配备的期望以及允许根据当地情况进行调整对于最大化影响很重要。